[1] Chien LH, Tseng TJ, Chen CH, et al. Comparison of annual percentage change in breast cancer incidence rate between Taiwan and the United States-A smoothed Lexis diagram approach[J]. Cancer Med, 2017, 6(7):1762-1775. DOI:10.1002/cam4.1102.
[2] Debourdeau P, Espié M, Chevret S, et al. Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients:the CAVECCAS study[J]. Cancer Med, 2017, 6(11):2732-2744. DOI:10.1002/cam4.1201.
[3] Wang S, Li Y, Li C, et al. Distribution and Determinants of Unmet Need for Supportive Care Among Women with Breast Cancer in China[J]. Med Sci Monit, 2018, 24:1680-1687. DOI:10.12659/MSM.905282.
[4] Terry MB, Bradbury A. Family-based Breast Cancer Prevention Efforts in Adolescence[J]. Pediatrics, 2016, 138(Suppl 1):S78-S80. DOI:10.1542/peds.2015-4268K.
[5] Todhunter ME, LaBarge MA. Cell and Tissue Biology Paves a Path to Breast Cancer Prevention[J]. Trends Cancer, 2017, 3(5):313-315. DOI:10.1016/j.trecan.2017.03.001.

Arenas M, García-Heredia A, Cabré N, et al. Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients[J/OL]. PLoS One, 2017, 12(11): e0188633[2018-01-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703554.DOI:10.1371/journal.pone.0188633.

[7] EER H, Small W. Intraoperative Radiotherapy for Breast Cancer[J]. Front Oncol, 2017, 7:317. DOI:10.3389/fonc.2017.00317.
[8] Saiki H, Petersen IA, Scott CG, et al. Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer[J]. Circulation, 2017, 135(15):1388-1396. DOI:10.1161/CIRCULATIONAHA.116.025434.
[9] Zhou Y, Wang C, Liu X, et al. Long non-coding RNA HOTAIR enhances radioresistance in MDA-MB231 breast cancer cells[J]. Oncol Lett, 2017, 13(3):1143-1148. DOI:10.3892/ol.2017.5587.
[10] Qi XS, Pajonk F, McCloskey S, et al. Radioresistance of the breast tumor is highly correlated to its level of cancer stem cell and its clinical implication for breast irradiation[J]. Radiother Oncol, 2017, 124(3):455-461. DOI:10.1016/j.radonc.2017.08.019.
[11] Roeszler KN, Itman C, Sinclair AH, et al. The long non-coding RNA, MHM, plays a role in chicken embryonic development, including gonadogenesis[J]. Dev Biol, 2012, 366(2):317-326. DOI:10.1016/j.ydbio.2012.03.025.
[12] Luan W, Zhou Z, Ni X, et al. Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis[J]. J Cancer Res Clin Oncol, 2018, 144(3):531-542. DOI:10.1007/s00432-018-2582-z.
[13] Li T, Liu Y, Xiao H, et al. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer[J]. Breast Cancer, 2017, 24(4):535-543. DOI:10.1007/s12282-016-0736-x.
[14] Liu X, Gan B. lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1[J]. Cell Cycle, 2016, 15(24):3471-3481. DOI:10.1080/15384101.2016.1249545.

Xiao ZD, Liu X, Zhuang L, et al. NBR2: A former junk gene emerges as a key player in tumor suppression[J/OL]. Mol Cell Oncol, 2016, 3(4): e1187322[2018-01-27]. https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC4972102. DOI: 10.1080/23723556.2016.1187322.

[16] Liu X, Xiao ZD, Han L, et al. LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress[J]. Nat Cell Biol, 2016, 18(4):431-442. DOI:10.1038/ncb3328.
[17] Secginli S, Nahcivan NO, Gunes G, et al. Interventions Promoting Breast Cancer Screening Among Turkish Women With Global Implications:A Systematic Review[J]. Worldviews Evid Based Nurs, 2017, 14(4):316-323. DOI:10.1111/wvn.12245.
[18] Yu C, Wang J. A Physical Mechanism and Global Quantification of Breast Cancer[J]. PLoS One, 2016, 11(7):e0157422[2018-01-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943646. DOI:10.1371/journal.pone.0157422.
[19] 李敏, 孟庆慧, 胡旭东, 等. B细胞易位基因2的表达水平对肿瘤细胞放射敏感性的影响[J].国际放射医学核医学杂志, 2013, 37(3):129-134. DOI:10.3760/cma.j.issn.1673-4114.2013.03.001.
Li M, Meng QH, Hu XD, et al. Effect of B-cell translocation gene 2 alteration on radiosensitivity of cancer cells[J]. Int J Radiat Med Nucl Med, 2013, 37(3):129-134.  doi: 10.3760/cma.j.issn.1673-4114.2013.03.001
[20] Chen MY, Chen YS, Hu LJ, et al. The end-of-treatment telephone response and prognosis of post-radiotherapy nasopharyngeal carcinoma patients in southern China[J]. Int J Clin Exp Med, 2015, 8(9):16564-16570.
[21] Zhang Y, Hui ZG, Zhang JH, et al. Survey on the use of radiotherapy to treat early breast cancer following breast-conserving surgery in China[J]. Tumori, 2014, 100(5):512-517. DOI:10.1700/1660.18166.
[22] Kim YG, Yoon YN, Choi HS, et al. Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion:clinical implications for serum HER2 in recurrent HER2-negative breast cancer[J]. Oncotarget, 2018, 9(5):5811-5822. DOI:10.18632/oncotarget.23528.
[23] Sims EK, Lakhter AJ, Anderson-Baucum E, et al. MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells[J]. Diabetologia, 2017, 60(6):1057-1065. DOI:10.1007/s00125-017-4237-z.
[24] Vartak SV, Hegde M, Iyer D, et al. A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis[J]. Biochem Pharmacol, 2016, 122:10-22. DOI:10.1016/j.bcp.2016.09.028.
[25] Min KW, Kim DH, Do SI, et al. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer[J]. Postgrad Med J, 2016, 92(1094):707-714. DOI:10.1136/postgradmedj-2015-133531.
[26] Bouchalova K, Kharaishvili G, Bouchal J, et al. Triple negative breast cancer-BCL2 in prognosis and prediction. Review[J]. Curr Drug Targets, 2014, 15(12):1166-1175.  doi: 10.2174/1389450115666141106151143
[27] Eom YH, Kim HS, Lee A, et al. BCL2 as a Subtype-Specific Prognostic Marke r for Breast Cancer[J]. J Breast Cancer, 2016, 19(3):252-260. DOI:10.4048/jbc.2016.19.3.252.
[28] Kordezangeneh M, Irani S, Mirfakhraie R, et al. Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles[J]. Med Oncol, 2015, 32(7):208. DOI:10.1007/s12032-015-0652-5.
[29] 姜勉, 董佳丽, 李航, 等. HBXIP蛋白表达对宫颈癌细胞的增殖能力及放射敏感性的影响[J].国际放射医学核医学杂志, 2017, 41(5):340-346. DOI:10.3760/cma.j.issn.1673-4114.2017.05.007.
Jiang M, Dong JL, Li H, et al. Effects of HBXIP protein expression on the proliferation and radiosensitivity of cervical cancer cells[J]. Int J Radiat Med Nucl Med, 2017, 41(5):340-346.  doi: 10.3760/cma.j.issn.1673-4114.2017.05.007
[30] Azimian H, Dayyani M, MTB T, et al. Bax/Bcl-2 expression ratio in prediction of response to breast cancer radiotherapy[J]. Iran J Basic Med Sci, 2018, 21(3):325-332. DOI:10.22038/IJBMS.2018. 26179. 6429.
[31] Li JY, Li YY, Jin W, et al. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL[J]. J Exp Clin Cancer Res, 2012, 31:102. DOI:10.1186/1756-9966-31-102.
[32] Abdel-Fatah TM, Perry C, Dickinson P, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings[J]. Ann Oncol, 2013, 24(11):2801-2807. DOI:10.1093/annonc/mdt277.